Клинические рекомендации (проект) по ведению и терапии новорожде. Клинические рекомендации по ведению и терапии новорожденных с заболеваниями надпочечников
 Скачать 0.76 Mb.
|
|
17. Shulman D. I., Palmert M. R., Kemp S. F. Adrenal Insufficiency: Still a Cause of Morbidity and Death in Childhood // Pediatrics. 2007. Vol. 119, N 2. P. e484–e494. 18. Als H., Lawhon G., Duffy F. H. et al. The individual development of care for very low birthweight premature infants. Medical and neurofunctional effects // JAMA. 1994. Vol. 272. P. 853–858. 19. Ng P. C., Lee C. H., Lam C. W. K. et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants // Arch. Dis. Child. Fetal. Neonatal. Ed. 2004. Vol. 89, N 2. P. 119–126. 20. Ng P. C. Is there a «normal» range of serum cortisol concentration for preterm infants? // Pediatrics. 2008. Vol. 122, N 4. P. 873–875. 21. Полин Р. А., Спитцер А. Р. М. Секреты неонатологии и перинатологии. М., 2011. 624 с. 22. Неонатология: Учебное пособие в 2 т. / Ред. Н. П. Шабалов. М.: МЕДпресс-информ, 2009. 640 с. 23. Annane D., Bellissant E., Bollaert P. E. et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis // BMJ. 2004. Vol. 329. P. 480–488. 24. Prigent H., Maxime V., Annane D. Clinical review: corticotherapy in sepsis // Crit. Care. 2004. Vol. 8. P. 122–129. 25. Annane D., Sebille V., Troche G. et al. A 3 level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotrophin // JAMA. 2000. Vol. 283. P. 1038–1045. 26. Arafah B. M. Hypothalamic pituitary adrenal function during critical illness: limitation of current assessment methods // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 3725–3745. 27. Cooper M. S., Stewart P. M. Corticosteroid insufficiency in acutely III patients // N. Engl. J. Med. 2003. Vol. 348. P. 727–734. 28. Donaldson A., Nicolini U., Symes E. K. et al. Changes in concentrations of cortisol, dehydroepiandrosterone sulphate and progesterone in fetal and maternal serum during pregnancy // Clin. Endocrinol. (Oxf). 1991. Vol. 35. P. 447–451. 29. Ward R. M., Kimura R. E., Rich-Denson C. Addisonian crisis in extremely premature neonates // Clin. Res. 1991. Vol. 39. P. 11A. 30. Посібник з неонатології: Пер. з англ. / Ред. Джон П. Клоерті, Ерік К. Ейхенвальд, Енн Р. Старк. Шосте видання. К.: Фонд допомоги і розвитку дітям Чорнобиля; Вид-во «Фенікс», 2010. 856 с. 31. Arnold J. D., Bonacruz G., Leslie G. I. et al. Antenatal glucocorticoids modulate the amplitude of pulsatile cortisol secretion in premature neonates // Pediatr. Res. 1998. Vol. 44. P. 876–881. 32. Soliman A. T., Taman K. H., Rizk M. M. et al. Circulating adrenocorticotropic hormone (ACTH) and cortisol concentrations in normal, appropriate for gestational age newborns versus those with sepsis and respiratory distress: cortisol response to low-dose and standard-dose ACTH tests // Metabolism. 2004. Vol. 53. P. 209–214. 33. Tantavit P., Subramanian N., Garg M. et al. Low serum cortisol in term newborns with refractory hypotension // J. Perinatol. 1999. Vol. 19. P. 352–357. 34. Fernandez E. F., Montman R., Watterberg K. L. ACTH and cortisol response to critical illness in term and late preterm newborns // J. Perinatol. 2008. Vol. 28. P. 797–802. 35. Soni A., Pepper G. M., Wyrwinski P. M. et al. Adrenal insufficiency occurring during septic shock: incidence, outcome and relationship to peripheral cytokine levels // Am. J. Med. 1995. Vol. 98. P. 266–271. 36. Ng P. C., Lam C. W. K., Fok T. F. et al. Refractory hypotension in preterm infants with adrenocortical insufficiency // Arch. Dis. Child. Fetal. Neonatal. Ed. 2001. Vol. 84, N 2. P. 122–124. 37. Watterberg K. L., Shaffer M. L., Mishefske M. J. et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants // Pediatrics. 2007. Vol. 120. P. 40–48. 38. Alatzoglou K., Dattani M. Genetic forms of hypopituitarism and their manifestation in the neonatal period // Early Human Dev. 2009. Vol. 85. P. 705–712. 39. Dempsher D. Аdrenal and pituitary insufficiency in infants // NeoReviews. 2008. Vol. 9. P. 72–77. 40. Диагностика и лечение эндокринных заболеваний у детей и подростков: Учебн. Пособие / Под ред. Проф. Н. П. Шабалова. М.: МЕДпресс-информ, 2009. 528 с. 41. Эндокринология (учебник) / Н. Лавин (ред.). М.: Практика, 1999. 42. Noble D. W. Dose Effects of Steroids on Survival in Sepsis // Ann Intern Med. 2004. Vol. 141. P. 891. 43. Функции надпочечников у плодов, новорожденных и грудных детей / Под ред. В. А. Таболина. М.: Медицина, 1975. 263 с. 44. Pang S., Shook M. K. Current status of neonatal screening for congenital adrenal hyperplasia // Curr. Opin. Pediatr. 1997. Vol. 9. P. 419–423. 45. Wilson T. A. Congenital Adrenal Hyperplasia. URL: http://emedicine.medscape.com/article/ 919218 overview (Дата доступа: 13.12.2012). 46. Prader A. Siebenman R. E. Nebenniereninsuffizienz bei kongenitaler Lipoidhyperplasie der Nebennieren // Helv. Paediat. Acta. 1957. Vol. 12, N 6. P. 569–595. 47. Pang S. Y., Wallace M. A., Hofman L. et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21 hydroxylase de ficiency // Pediatrics 1988. Vol. 81, N 6. P. 866– 874. 48. White P. C. Neonatal screening for congenital adrenal hyperplasia // Nat. Rev. Endocrinol. 2009. Vol. 5, N 9. P. 490–8. 49. Кроненберг Г. М., Мелмед Ш., Полонски К. С., Ларсен П. Р. Заболевания коры надпочечников и эндокринная артериальная гипертензия. М., 2009. 208 с. 50. Debre R., Semelaigne G. Hypertrophie considerable des capsules surrenales chez un nourrison mort a 10 mois sans avoir augment? // Bull. Soc. Pediat. Paris, 1925. Vol. 23. P. 270–271. 51. Пилипенко В. М. Уроджена дисфункція кори надниркових залоз // Ендокринологія. 2010. Т. 15, № 1. С. 140–159. 52. Al-Saedi S., Dean H., Dent W., Cronin C. Reference ranges for serum cortisol and 17 hydroxyprogesterone levels in preterm infants // J. Pediatr. 1995. Vol. 126. P. 985–987. 53. Antal Z., Zhou P. Congenital Adrenal Hyperplasia Diagnosis, assessment and management // Pediatrics in Review. 2009. Vol. 30 N 7. P. 49–57. 54. Auchus R. J., Miller W. L. Congenital adrenal hyperplasia — more dogma bites the dust // J. Clin. Endocrinol. Metab. 2012. Vol. 97, N 3. P. 772–775. 55. Speiser P., Azziz R., Baskin L. et al. Congenital adrenal hyperplasia due to steroid 21 hydroxylase deficiency: an Endocrine Society clinical practice guideline // J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 4133–4160. 56. Purandare A., Godil M. A., Prakash D. et al. Spontaneous adrenal hemorrhage associated with transient antiphospholipid antibody in a child // Clin. Pediatr. (Phila). 2001. Vol. 40, N 6. P. 47–50. 57. Finkielstain G. P., Chen W., Mehta S. P. et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21 hydroxylase deficiency // J. Clin. Endocrinol. Metab. 2011. Vol. 96. P. 161–172. 58. Witchel S. F. Nonclassic congenital adrenal hyperplasia // Curr. Opin. Endocrinol. Diabetes Obes. 2012. Vol. 19, N 3. P. 151–158. 59. Votava F. et al. Estimation of the false negative rate in newborn screening for congenital adrenal hyperplasia // Eur. J. Endocrinol. 2005. Vol. 152. P. 869–874. 60. Kagimoto M., Winter J. S., Kagimoto K. et al. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha- hydroxylase/17,20 lyase de ficiency // Mol. Endocrinol. 1988. Vol. 2, N 6. P. 564–570. 61. JOINT LWPES/ESPE CAH Working Group. Consensus statement on 21 hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology // J. Clin. Endocrinol. Metab. 2002. Vol. 87, N 9. P. 4048–53. 62. Lin-Su K., Harbison M. D., Lekarev O. et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone // J. Clin. Endocrinol. Metab. 2011. Vol. 96, N 6. P. 1710–1717. 63. Carlson A. D., Obeid J. S., Kanellopoulou N. et al. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment // J. Steroid. Biochem. Mol. Biol. 1999. Vol. 69, N 1–6. P. 19–29. 64. Hirvikoski T, Nordenstro A., Wedell A. et al. Prenatal Dexamethasone Treatment of Children at Risk for Congenital Adrenal Hyperplasia: The Swedish Experience and Standpoint // J. Clin. Endocrin. Metab. doi:10.1210/jc.2012–1222. 65. Meyer-Bahlburg H. F., Dolezal C., Haggerty R. et al. Cognitive Outcome of Offspring from Dexamethasone-Treated Pregnancies at Risk for Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency // Eur. J. Endocrinol. 2012. Vol. 167. P. 103–110. 66. Janzen N., Riepe F. G., Peter M. et al. Neonatal screening: identification of children with 11 β-hydroxylase deficiency by second-tier testing // Horm. Res. Paediatr. 2012. Vol. 77, N 3. P. 195–199. 67. Rohrer T. R., Gassmann K. F., Pavel M. E. et al. Pitfall of newborn screening for congenital adrenal hyperplasia due to 21 hydroxylase deficiency // Biol. Neonate. 2003. Vol. 83. P. 65–68. 68. Garner P. R. Congenital adrenal hyperplasia in pregnancy // Semin. Perinatol. 1998. Vol. 22, N 6. P. 446– 456. 69. Aycan Z., Akbuga S., Cetinkaya E., et al. Final height of patients with classical congenital adrenal hyperplasia // Turk J Pediatr. 2009. Vol. 51 (6). P. 539–544. |